NeuroPace Inc
NeuroPace develops and sells medical devices for people with epilepsy. Its main product is the RNS System, an implantable, brain-responsive neuromodulation system currently approved in the United States for adults with drug-resistant focal epilepsy. The system monitors and records brain activity, detects patient-specific abnormal patterns, and delivers electrical stimulation at the seizure source. It includes an implanted neurostimulator and leads, a patient monitor, a physician tablet, and software and platforms for data management, remote monitoring, and clinician support. NeuroPace sells systems for initial implants and replacement devices, and provides products and services that support ongoing monitoring and programming. Clinicians and hospitals receive reimbursement for implant procedures and follow-up care, including review of brain activity data. NeuroPace also has limited distribution sales in Israel and a special access program in Canada. Its commercial efforts primarily serve epilepsy centers, epileptologists, and neurosurgeons in the United States. NeuroPace is headquartered in Mountain View, California.
No SEC Form 4 filings for $NPCE in the last 30 days.
See all $NPCE insider activity →NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth Revises full year 2026 revenue guidance to $91 million to $92 million; focused on i
NeuroPace (NPCE) reported Q3 2026 revenue of $23.1M, down 1.1% YoY. Non-GAAP operating income was $0.4M, improving from a $1.4M loss. The company noted revenue missed expectations and had $49.5M in cash at quarter-end, down from $51.9M.
Analysts made several rating changes: BTIG upgraded Etsy to Buy with a $90 target, JPMorgan upgraded Tyson Foods to Overweight with a $63 target, Mizuho initiated Boyd Group as Outperform with a $120 target, TD Cowen upgraded Targa Resources to Buy with a $350 target, Barclays initiated Tower Semiconductor as Overweight, Stifel upgraded Yeti to Buy with a $50 target, Citi upgraded Stubhub to Buy, KeyBanc initiated NeuroPace as Overweight, UBS upgraded Waste Connections to Buy, Bank of America in
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning NPCE (NeuroPace Inc). Coverage has skewed bearish: 0 bullish, 0 neutral, and 4 bearish.
Recent NPCE coverage spans financial news, earnings and corporate actions.
Updated guidance suggests slower growth, likely pressuring the stock.
Revenue miss and lower operating income suggest short‑term pressure on the stock.
Overweight initiation may lift NeuroPace.
Guidance raise plus RNS revenue growth and margin outlook improvement are likely to support near-term sentiment, despite after-market weakness.
Guidance raise plus continued RNS adoption momentum is likely to support near-term sentiment, while cash burn and FDA path for the IGE PMA supplement remain key risk drivers.
AlphAI scores every news story that mentions NPCE with an AI model for sentiment and relevance, and aggregates insider trades from NeuroPace Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth Revises full year 2026 revenue guidance to $91 million to $92 million; focused on i
NeuroPace (NPCE) reported Q3 2026 revenue of $23.1M, down 1.1% YoY. Non-GAAP operating income was $0.4M, improving from a $1.4M loss. The company noted revenue missed expectations and had $49.5M in cash at quarter-end, down from $51.9M.
Analysts made several rating changes: BTIG upgraded Etsy to Buy with a $90 target, JPMorgan upgraded Tyson Foods to Overweight with a $63 target, Mizuho initiated Boyd Group as Outperform with a $120 target, TD Cowen upgraded Targa Resources to Buy with a $350 target, Barclays initiated Tower Semiconductor as Overweight, Stifel upgraded Yeti to Buy with a $50 target, Citi upgraded Stubhub to Buy, KeyBanc initiated NeuroPace as Overweight, UBS upgraded Waste Connections to Buy, Bank of America in
NeuroPace (NPCE) reported Q2 2026 EPS loss of 18 cents, better than the Zacks Consensus by 5.3%. Revenue rose 17.1% to $22.8 million, with RNS revenue up 21.3% to $22.5 million. Cash and short-term investments were $51.7 million. Full-year 2026 revenue guidance was raised to $99.5-$101.5 million.
NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which a
NeuroPace Inc (NPCE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K NeuroPace Inc false 0001528287 0001528287 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event report
NeuroPace Inc's CFO, Patrick F. Williams, has received equity compensation awards comprising 16,820 restricted stock units (RSUs) and stock options for 44,800 shares. These awards, detailed in a recent Form 4 filing, are part of his compensation and are not open-market transactions. The RSUs and stock options have specific vesting schedules, with initial vesting in May 2027 and subsequent installments designed to align the CFO's long-term incentives with the company's performance.
NeuroPace (NPCE) reported Q4 2025 revenue of US$26.6 million and an EPS loss of US$0.08, with trailing twelve-month revenue at US$100.0 million and an EPS loss of US$0.66. While revenue is growing and losses are narrowing, the company remains unprofitable, leading to a tension between bullish expectations for future growth and current valuation metrics. The stock trades at a P/S premium compared to the industry and peers, and above its DCF fair value, prompting caution despite analyst growth projections.
NeuroPace, Inc. announced it will report its financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. A conference call and webcast will follow at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) for investors to participate and listen to the discussion. The webcast will be archived on the company's investor relations website for replay.
Image source: The Motley Fool.Tuesday, Nov. 4, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
